Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 14/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.43 |
| ▸ | JUN | P05412 | 3/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416391 | 0.85 | PSEN1 (0.56) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL415309 | 0.82 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL416273 | 0.82 | PSEN1 (0.48) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL417451 | 0.81 | MAPK10 (0.43) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL416502 | 0.79 | PSEN1 (0.43) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL414849 | 0.76 | PSEN1 (0.62) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL416395 | 0.76 | PSEN1 (0.46) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL414793 | 0.74 | PSEN1 (0.48) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL412563 | 0.74 | PSEN1 (0.56) | MAPK10MAPK8JUNPSEN1PSEN2 | |
| SCHEMBL414499 | 0.73 | PSEN1 (0.56) | MAPK10JUNPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772504-B2 | Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | MAPK10 4737/4885MAPK8 4354/4885JUN 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.